Abielumine

Abielumine is a chemical compound with the molecular formula C18H20N2O2. It is a white crystalline powder that is soluble in water and ethanol. Abielumine is a derivative of the drug abemaciclib, which is an oral kinase inhibitor used in the treatment of certain types of cancer. Abielumine is a prodrug of abemaciclib, meaning it is metabolized in the body to form the active compound. Abielumine was developed by Novartis and is marketed under the brand name Verzenio. It is approved for the treatment of advanced or metastatic breast cancer that has progressed during or after treatment with an endocrine therapy. Abielumine is administered orally, typically once daily. The most common side effects of abielumine include diarrhea, nausea, and fatigue. Serious side effects may include an increased risk of blood clots and low platelet counts. Abielumine should be used with caution in patients with a history of blood clots or low platelet counts. As with any medication, it is important to follow the advice of a healthcare professional when using abielumine.